GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in…
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster…
Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12…
The New Statements Guide the Foundation’s 2025-2028 Strategic PlanBOWIE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- After more than 50…
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences…
LONDON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini…
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,…
Health plan focuses on evolving community needs while renewing longstanding commitment to address inequities, promote greater healthEAGAN, Minn., Sept. 23,…
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential…